Request the Llusern investor pack
Llusern Scientific is developing treatment-directing diagnostics that support faster, better-informed treatment decisions. Its first focus is Lodestar DX, a portable molecular UTI testing system designed for near-patient use by professional users.
For further information on the company, product, commercial model and progress to date, request the Llusern investor pack.
A focused diagnostics company with a clear first product
Llusern is starting with rapid UTI testing, a common diagnostic need where faster information can support better-informed treatment decisions.
Lodestar DX brings molecular UTI testing closer to the patient, with a portable system designed for professional clinical use.
Key information at a glance
Clear first product
Near-patient molecular testing
Less than 40 minutes
35 minute test run-time.
Professional-use settings
Device-plus-consumables opportunity
Broader platform potential
A practical product for a recurring diagnostic need
Lodestar DX is designed around speed, portability and simplicity. It detects six key UTI-causing bacterial pathogens from a small urine sample, requires only 10 μL of urine and does not require an extraction step.
This gives Llusern a focused product opportunity in rapid UTI testing, with relevance across professional healthcare settings.
Built by a credible multidisciplinary team
Llusern Scientific brings together specialists in microbiology, molecular genetics, engineering, product development, quality management, regulatory compliance, urology, infectious disease and commercial strategy.
Together, the team is building accessible diagnostic technology designed to help healthcare professionals make faster, better-informed treatment decisions.
Martyn Lewis
Dr Emma Hayhurst
Professor Bob Yang
Laurence Tisi
Request investor pack
To receive the Llusern investor pack, please complete the form below. Some information may be shared following review and, where appropriate, under confidentiality arrangements.
